HR and breast cancer: CCNE1 amplification leads to acquisition of resistance to CDK4/6 inhibition, owing to the bypass of cyclin D1-CDK4/6 dependency (Herrera-Abreu et al., 2016), which is highly expressed in the high-risk group among patients with HR+ or HER2− BC.